European Nanomedicine Translation Advisory Board selects and welcomes new projects in Base

If you have a promising project in Nanomedicine, don’t miss out the opportunity to apply to the TAB – Nanomedicine Translation Advisory Board until the 8th of May 2016!

The TAB provides you unique, free of charge access to high-level experts, who will advise and guide you to accelerate your project to the market. The TAB wants to help you to make the right strategic choices at the right time, reducing risks and maximizing the chances of success. Please check what current beneficiaries said about the TAB. TESTIMONIALS

Who can apply?

European companies, public and private research groups / individuals working on promising Nanomedicine projects at any stage of development.

Who are the high-level experts?
The TAB experts are coming from the pharma and healthcare industries, including biotech and nanotech entrepreneurs, and former top managers at large corporations. All the experts have a sound track record in translating promising concepts to market success.

What is the process?

Hard selection based on application files
Individual mentoring during live sessions (TAB-In Sessions)
Follow up of selected projects (follow up content depending on specific needs, and until the moment that chances of success exist)
What are the TAB-In Sessions?

The TAB-In Sessions are the entry point
for projects selected to benefit from the TAB. They provide beneficiaries the unique opportunity of benefiting from face-to-face meetings to get experts’ initial feedback and recommendations. The TAB-In Sessions should normally take place during relevant larger events or business conferences (e.g. ETPN Annual Event, CLINAM, Bio-Europe). The ongoing Second Call will provide selected projects with access to the TAB-In Sessions to be held on the 28th of June, in Basel (Switzerland). Basel will be The nanomedicine hotspot, hosting other two major events (CLINAM and the Swiss Nanoconvention 2016).

Apply here!

Further information about the TAB can be found at

TAB Press Release (211 KB), click here

Our mailing address is:

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *